Fibromyalgia is a central sensitisation disorder and agmatine is a GluN2B-selective NMDA antagonist, which is why the question gets asked. Here is why the strongest agmatine pain data is also the hardest to apply.
Acute stress raises brain agmatine nearly fourfold. Chronic stress depletes it. That apparent contradiction is the most useful thing in this literature, and no PTSD study exists.
Agmatine depletes cellular polyamines and slows hepatoma cell growth in a dish. It is also lower in the blood of prostate cancer patients. Neither finding says what supplement marketing wants it to say.
Agmatine protects rodent livers against valproate, cisplatin and endotoxin-induced failure. Every study is prophylactic, in animals, and one of them carries a safety warning most articles skip.
In Alzheimer’s models, brain agmatine falls and its degrading enzyme rises. That biomarker story is better supported than any claim that supplementing agmatine treats Alzheimer’s.
Agmatine protects dopamine neurons in rodent models of Parkinson’s and even abolishes L-dopa dyskinesia in rats. Here is the full preclinical picture, and the dose arithmetic nobody publishes.
In the standard animal model of MS, agmatine restored a blood-brain barrier tight junction protein and lowered the enzymes that break the barrier down. Why that’s a research lead, not a treatment.
A rat study put agmatine head-to-head against methylprednisolone after spinal cord injury. Both cut oxidative damage markers – here’s what that does and doesn’t mean.
Topical agmatine cut retinal ganglion cell loss from 55% to 19% in a rat glaucoma model. Why that doesn’t transfer to capsules, and the retracted paper still circulating as evidence.
Agmatine reduced seizures in chronic models, did nothing in acute ones, and measurably weakened vigabatrin in mice. A rare case where the contradictions in the evidence are the story.
Rodent stroke models show large infarct reductions with agmatine – and a hard 5-hour limit on when it still works. What the cerebral ischemia literature does and doesn’t establish.
Rat TBI studies show agmatine cuts brain edema by suppressing aquaporin water channels and reduces apoptotic cell death. Here’s the mechanism, and the large gap between it and human use.